Delaware/Christiana Care (CCHS) Community Oncology Research Program was originally funded as a Community Clinical Oncology Program (CCOP) in 1987, and was funded as a NCI Community Cancer Centers Program beginning in 2007 and has been an exemplary contributor to both programs. Currently, CCHS participates in the NRG, ALLIANCE, ECOG-ACRIN, Wake Forest and Rochester cooperative groups. The CCOP continues to fulfill research obligations for the cooperative group legacy groups including: CALGB, NSABP, ECOG, RTOG, GOG, Wake Forest and URCC. Participation in CTSU is active and ongoing. Our extensive catchment area includes all of Delaware and portions of New Jersey, northeastern Maryland and southeastern Pennsylvania (Delaware and Chester counties). Delaware ranks 3rd in the nation for all cancer site disease incidence, Maryland ranks 35th, New Jersey 5th and Pennsylvania 6th (2007 uses Data). Our research base represents a population base in excess of 2 million people with extensive protocol entry potential. Under the leadership of Stephen S.Grubbs, M.D., Principal Investigator, Gregory Masters, M.D, Co-Principal Investigator and Kandie Dempsey, MS, RN, OCN, Director, CCOP investigators, project coordinators and data managers will continue to participate in National Clinical Trial network (NCTN) core committees and leadership positions. Our mission is to continue accruals to both treatment and cancer control studies and to further develop Cancer Care Delivery Research (CCDR) participation which will build upon the initiatives set forth with our collaboration in NCCCP. We anticipate dedicating at minimum 10% of our activities towards CCDR to include scientific investigation of the complexities of social factors, organizational structures and processes, health technologies, access to cancer care, quality and cost factors, disparities in our community. And will examine the feasibility of examining financial costs of care and health technology systems as part of the CCDR program. The overall impact of this grant will be to ensure continuation and stimulate expansion of CCOP activities, including treatment and cancer control research, at Christiana Care Health Services and its affiliates throughout the catchment area. The Delaware/CCHS CCOP has consistently rated amongst top in the nation for clinical trial accruals. Over the past three years the accrual rate has been 24.8% in 2010, 24% in 2011 and 21.4% in 2012.
Our mission statement is to provide the community with coordinated access to cancer related clinical trials in order to reduce cancer incidence, morbidity and mortality while improving quality of life. Participation in the NCORP provides us with the opportunity to work towards our mission.
|Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58|
|Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050|
|Shapiro, Charles L; Moriarty, James P; Dusetzina, Stacie et al. (2017) Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance). J Clin Oncol 35:3949-3955|
|Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340|
|Martin, P; Jung, S-H; Pitcher, B et al. (2017) A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). Ann Oncol 28:2806-2812|
|Enzinger, Peter C; Burtness, Barbara Ann; Niedzwiecki, Donna et al. (2016) CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. J Clin Oncol 34:2736-42|
|Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42|
|Masters, Gregory A; Wang, Xiaofei; Hodgson, Lydia et al. (2011) A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531. Lung Cancer 74:258-63|